BACKGROUND: There is a need to find cognitive markers that can help identify individuals at risk for Alzheimer's disease (AD), and that can be used to reliably measure cognitive decline. OBJECTIVE: We tested whether a theoretically driven three-factor structure would characterize cognitive functioning in individuals who are genetically-determined to develop AD due to a mutation in Presenilin-1 (PSEN1) gene. We also examined whether these factors could distinguish cognitively unimpaired PSEN1 mutation carriers from age-matched non-carrier family members. METHODS: 1,395 cognitively unimpaired members of a Colombian kindred with the PSEN1 E280A mutation were included in the study. A confirmatory factor analysis examined the fit of the three-factor model comprising episodic memory (MMSE memory recall, CERAD-COL Word list recall, and Constructional praxis recall), executive function (Phonemic fluency and WCST perseverative errors), and psychomotor processing speed (TMT-A and WAIS-III Digit Symbol). RESULTS: The three-factor model provided an excellent fit for all participants (p = 0.24; RMSEA = 0.01). Further, the episodic memory (p = 0.0004, d = 0.25) and executive functioning (p = 0.001, d = 0.18) factors distinguished cognitively unimpaired carriers from non-carriers. The episodic memory factor provided the earliest indication of preclinical cognitive decline at 35 years of age, nine years before individuals' estimated age of clinical onset. CONCLUSIONS: The three theoretically derived cognitive factors provide a reliable measure of cognition and may be useful for the early detection of AD, as well as for measuring disease progression. However, longitudinal studies are needed to confirm that these factors can be used to track the progression of cognitive decline in preclinical AD.
BACKGROUND: There is a need to find cognitive markers that can help identify individuals at risk for Alzheimer's disease (AD), and that can be used to reliably measure cognitive decline. OBJECTIVE: We tested whether a theoretically driven three-factor structure would characterize cognitive functioning in individuals who are genetically-determined to develop AD due to a mutation in Presenilin-1 (PSEN1) gene. We also examined whether these factors could distinguish cognitively unimpaired PSEN1 mutation carriers from age-matched non-carrier family members. METHODS: 1,395 cognitively unimpaired members of a Colombian kindred with the PSEN1E280A mutation were included in the study. A confirmatory factor analysis examined the fit of the three-factor model comprising episodic memory (MMSE memory recall, CERAD-COL Word list recall, and Constructional praxis recall), executive function (Phonemic fluency and WCST perseverative errors), and psychomotor processing speed (TMT-A and WAIS-III Digit Symbol). RESULTS: The three-factor model provided an excellent fit for all participants (p = 0.24; RMSEA = 0.01). Further, the episodic memory (p = 0.0004, d = 0.25) and executive functioning (p = 0.001, d = 0.18) factors distinguished cognitively unimpaired carriers from non-carriers. The episodic memory factor provided the earliest indication of preclinical cognitive decline at 35 years of age, nine years before individuals' estimated age of clinical onset. CONCLUSIONS: The three theoretically derived cognitive factors provide a reliable measure of cognition and may be useful for the early detection of AD, as well as for measuring disease progression. However, longitudinal studies are needed to confirm that these factors can be used to track the progression of cognitive decline in preclinical AD.
Authors: Daniel C Aguirre-Acevedo; Francisco Lopera; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Shrikant I Bangdiwala; Eric M Reiman; Pierre N Tariot; Jessica B Langbaum; Yakeel T Quiroz; Fabian Jaimes Journal: JAMA Neurol Date: 2016-04 Impact factor: 18.302
Authors: Courtney L Sutphen; Mateusz S Jasielec; Aarti R Shah; Elizabeth M Macy; Chengjie Xiong; Andrei G Vlassenko; Tammie L S Benzinger; Erik E J Stoops; Hugo M J Vanderstichele; Britta Brix; Heather D Darby; Manu L J Vandijck; Jack H Ladenson; John C Morris; David M Holtzman; Anne M Fagan Journal: JAMA Neurol Date: 2015-09 Impact factor: 18.302
Authors: Emily C Edmonds; Katherine J Bangen; Lisa Delano-Wood; Daniel A Nation; Ansgar J Furst; David P Salmon; Mark W Bondi Journal: J Int Neuropsychol Soc Date: 2016-11 Impact factor: 2.892
Authors: Y T Quiroz; B A Ally; K Celone; J McKeever; A L Ruiz-Rizzo; F Lopera; C E Stern; A E Budson Journal: Neurology Date: 2011-07-20 Impact factor: 9.910
Authors: Yakeel T Quiroz; Chantal E Stern; Eric M Reiman; Michael Brickhouse; Adriana Ruiz; Reisa A Sperling; Francisco Lopera; Bradford C Dickerson Journal: J Neurol Neurosurg Psychiatry Date: 2012-11-07 Impact factor: 10.154
Authors: Edmarie Guzmán-Vélez; Jairo Martínez; Kate Papp; Ana Baena; Clara Vila-Castelar; Arabiye Artola; Aaron P Schultz; Yamile Bocanegra; Justin Sanchez; Dorene Rentz; Pierre N Tariot; Eric M Reiman; Reisa Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz Journal: Neurology Date: 2020-07-01 Impact factor: 9.910
Authors: Amir H Kashani; Samuel Asanad; Jane W Chan; Maxwell B Singer; Jiong Zhang; Mona Sharifi; Maziyar M Khansari; Farzan Abdolahi; Yonggang Shi; Alessandro Biffi; Helena Chui; John M Ringman Journal: Prog Retin Eye Res Date: 2021-01-15 Impact factor: 19.704
Authors: Daniel J Norton; Mario A Parra; Reisa A Sperling; Ana Baena; Edmarie Guzman-Velez; David S Jin; Nicholas Andrea; Juna Khang; Aaron Schultz; Dorene M Rentz; Enmanuelle Pardilla-Delgado; Joshua Fuller; Keith Johnson; Eric M Reiman; Francisco Lopera; Yakeel T Quiroz Journal: Alzheimers Res Ther Date: 2020-08-21 Impact factor: 6.982
Authors: Sascha Hansen; Jana Keune; Kim Küfner; Regina Meister; Juliane Habich; Julia Koska; Stefan Förster; Patrick Oschmann; Philipp M Keune Journal: BMC Neurol Date: 2022-03-09 Impact factor: 2.474
Authors: Ophir Keret; Adam M Staffaroni; John M Ringman; Yann Cobigo; Sheng-Yang M Goh; Amy Wolf; Isabel Elaine Allen; Stephen Salloway; Jasmeer Chhatwal; Adam M Brickman; Dolly Reyes-Dumeyer; Randal J Bateman; Tammie L S Benzinger; John C Morris; Beau M Ances; Nelly Joseph-Mathurin; Richard J Perrin; Brian A Gordon; Johannes Levin; Jonathan Vöglein; Mathias Jucker; Christian la Fougère; Ralph N Martins; Hamid R Sohrabi; Kevin Taddei; Victor L Villemagne; Peter R Schofield; William S Brooks; Michael Fulham; Colin L Masters; Bernardino Ghetti; Andrew J Saykin; Clifford R Jack; Neill R Graff-Radford; Michael Weiner; David M Cash; Ricardo F Allegri; Patricio Chrem; Su Yi; Bruce L Miller; Gil D Rabinovici; Howard J Rosen Journal: Alzheimers Dement (Amst) Date: 2021-07-05